Furthermore, dose reduction due to TEAEs occurred in only 3% (4/152) of patients in this study, compared with 16% for alectinib, 62% for ceritinib, and 14% for brigatinib.13,20,24 Taken together, WX-0593 had a good safety profile in patients with ALK- or ROS1-rearranged NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.